The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
This session features the top abstracts submitted and reviewed by the Liver & Biliary (LB) section, showcasing cutting-edge research and advancements in liver and biliary diseases. Attendees will gain insights into genetic and clinical predictors of mortality in steatotic liver disease, the impact of nutritional therapy on frailty status in cirrhotic patients, and the efficacy and safety of novel treatments for primary biliary cholangitis and hepatocellular carcinoma. Additionally, the session will explore the use of AI models for predicting advanced liver fibrosis and cardiovascular mortality in MASLD.
Alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) are often concomitant diseases. Compared to other liver disease, ALD often presents at an advanced stage and after presentation progresses faster to decompensation with a reduced patient survival…